Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…
Malignant Complications: Screening for Cancer in Rheumatic Diseases
Cancer and autoimmunity have a complex relationship. In a presentation, Ami Shah, MD, MHS, discussed how to use autoantibodies as tools for cancer risk stratification, how to approach cancer screening in individuals with new-onset disease and more…
Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients
In patients with active ankylosing spondylitis, IL-17 inhibitors have produced favorable responses, according to recent research…
ACR Releases Clinical Guidance for Patients with Multisystem Inflammatory Syndrome in Children
The recommendations for MIS-C focus on general guidance, diagnostic evaluation and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki disease.
ACR Releases COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease
The recommendations for pediatric rheumatology patients address various treatment options and provide general guidance, as well as direction for when to start, stop or reduce medications.
Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD
Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…
Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
COVID-19 Global Alliance registry and other data on rheumatic disease patients with COVID-19 were presented…
Unified Signature of SLE May Advance Clinical Diagnosis & Biomarker Development
Researchers have identified 93 genes that may play a role in systemic lupus erythematosus (SLE), including 47 genes not previously associated with SLE. Theresulting transcriptome has revealed underappreciated genes and pathways associated with the pathogenesis of SLE…
Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…
Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19
NEW YORK (Reuters Health)—Patients with some inflammatory rheumatic conditions are at higher risk for hospital-diagnosed COVID-19 infection compared with the general population, but it depends on the condition and therapy used to treat it, according to a study from Spain. It’s now clear that older patients and those with some common diseases are at increased…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 336
- Next Page »